Company intelligence / Profile preview
Jilin Huakang Pharmaceutical
Dunhua, Jilin, Chinamedhk.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Jilin Huakang Pharmaceutical is a leading Chinese pharmaceutical company with a focus on R&D and manufacturing of both traditional Chinese medicines and modern pharmaceuticals. The company has several products on the market and an active pipeline that includes small molecules and biologics targeting cardiovascular diseases such as angina. Clinical results include ongoing Phase 2/3 studies for key assets like Pseudo-Ginsenoside GQ injection[8].
- Therapeutic areas
- GastroenterologyCardiovascularImmunology
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
No major international pharma partnerships publicly disclosed.
Beyond the preview
Go deeper on Jilin Huakang Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jilin Huakang Pharmaceutical.